Pharma BD Deal Intelligence

AstraZeneca plc / Owkin, Inc.

2026 · Licensing/Option · Complete

Owkin and AstraZeneca signed a multi-year (three-year) license agreement for K Pro, Owkin's AI Scientist platform for biopharma decision making, under which Owkin will lead end-to-end development of AI agents that run on K Pro integrated into AstraZeneca's IT infrastructure and decision workflows. The agents are intended to give AstraZeneca teams data-rich answers to complex competitive-intelligence and R&D questions within existing governance and security standards. The agreement builds on prior Owkin-AstraZeneca work on an AI gBRCA pre-screen solution in breast cancer. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  AstraZeneca plc deals